Cell-Free and Erythrocytic S-Nitrosohemoglobin Inhibits Human Platelet Aggregation

JR Pawloski, RV Swaminathan, JS Stamler - Circulation, 1998 - Am Heart Assoc
JR Pawloski, RV Swaminathan, JS Stamler
Circulation, 1998Am Heart Assoc
Background—Nitric oxide (NO) and related molecules are thought to inhibit human platelet
aggregation by raising levels of cGMP. Methods and Results—Both oxidative stress
(reactive oxygen species) and hemoglobin (Hb) seem to oppose NO effects. A major fraction
of NO in the blood is bound to thiols of Hb, forming S-nitrosohemoglobin (SNO-Hb), which
releases the NO group on deoxygenation in the microcirculation. Here we show that (1) both
cell-free and intraerythrocytic SNO-Hb (SNO-RBC) inhibit platelet aggregation,(2) the …
Background—Nitric oxide (NO) and related molecules are thought to inhibit human platelet aggregation by raising levels of cGMP.
Methods and Results—Both oxidative stress (reactive oxygen species) and hemoglobin (Hb) seem to oppose NO effects. A major fraction of NO in the blood is bound to thiols of Hb, forming S-nitrosohemoglobin (SNO-Hb), which releases the NO group on deoxygenation in the microcirculation. Here we show that (1) both cell-free and intraerythrocytic SNO-Hb (SNO-RBC) inhibit platelet aggregation, (2) the oxidation state of the hemes in Hb influences the response—SNO-metHb (which is functionally similar to SNO-deoxyHb) has greater platelet inhibitory effects than SNO-oxyHb, and (3) the mechanism of platelet inhibition by SNO-Hb is cGMP independent.
Conclusions—We suggest that the RBC has evolved a means to counteract platelet activation in small vessels and the proaggregatory effects of oxidative stress by forming SNO-Hb.
Am Heart Assoc